Midatech forms scientific advisory board
This article was originally published in Scrip
Executive Summary
Abingdon, UK-based Midatech, which develops nanomedicines based on its gold-nanoparticle technology, has formed as scientific advisory board. The advisory board includes senior figures from research and industry with expertise in key areas including nanoparticles, materials chemistry, drug development and delivery, and patent protection; and will be chaired by Francesco Stellaci, Constellium professor and head of the supramolecular nanomaterials and interfaces laboratory at the École Polytechnique Fédérale de Lausanne.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.